BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
BHVN upcoming catalysts
Biohaven Therapeutics Ltd.: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 1 upcoming FDA decision event(s), and in the last 12 months 5 readout(s) and 0 FDA event(s). Subscribe to BHVN (.ics).
Drugs: BHV-7000
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2027-01-01 (quarter) | PDUFA date (company-disclosed) | pending | Biohaven Ltd. BHVN | PDUFA first quarter of 2027 - Biohaven Ltd. |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2/P3 | Biohaven Therapeutics Ltd. BHVN | NCT06132893 A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Focal Epilepsy | active not recruiting | 390 |
| 2026-12 est. | P2 | Biohaven Therapeutics Ltd. BHVN | NCT06443463 Long-term Safety and Tolerability of BHV-7000 | Focal Epilepsy | enrolling by invitation | 660 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P2/P3 | Biohaven Therapeutics Ltd. BHVN | NCT06309966 Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Focal Epilepsy | active not recruiting | 390 |
| 2026-09 est. | P2 | Biohaven Therapeutics Ltd. BHVN | NCT07281495 Taldefgrobep Alfa in Adults With Overweight and Obesity | Obesity; Overweight | active not recruiting | 150 |
| 2026-03-18 | P2 | Biohaven Therapeutics Ltd. BHVN | NCT06423781 Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) | Major Depressive Disorder | completed | 233 |
| 2026-03-12 | P2/P3 | Biohaven Therapeutics Ltd. BHVN | NCT06425159 A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures | Generalized Epilepsy | terminated | 27 |
| 2026-02-13 | P3 | Biohaven Pharmaceuticals, Inc. BHVN | NCT04708834 Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | terminated | 772 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.